The impact of topiramate, botulinum toxin type A, and CGRP-antibodies on medication overuse headache in patients with chronic migraine: A protocol for systematic review and meta-analysis
Medication overuse headache (MOH) is defined as headache occurring ≥15 days/month developing as a consequence of regular overuse of acute or symptomatic headache medication for more than 3 months. MOH is present in more than 50% of patients with chronic migraine (CM). Although, studies have shown a...
Main Authors: | Samita Giri, Erling Tronvik, Mattias Linde, Knut Hagen |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-04-01
|
Series: | Cephalalgia Reports |
Online Access: | https://doi.org/10.1177/25158163221096867 |
Similar Items
-
The bidirectional temporal relationship between headache and affective disorders: longitudinal data from the HUNT studies
by: Samita Giri, et al.
Published: (2022-01-01) -
Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
by: Armin Scheffler, et al.
Published: (2024-07-01) -
Headache disorders and risk of stroke: A register-linked HUNT study
by: Samita Giri, et al.
Published: (2024-11-01) -
Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization
by: Takafumi Tanei, et al.
Published: (2024-11-01) -
Effects of Topiramate in the Prevention of Drug Resistant Migraine Headache
by: H Khani, et al.
Published: (2009-04-01)